The minimum meaningful peptide protocol is one cycle
For type 2 diabetes management , licensed GLP-1 medications include: Exenatide (Byetta, Bydureon) available as twice-daily or once-weekly formulations Liraglutide (Victoza) administered once daily Dulaglutide (Trulicity) given once weekly Semaglutide (Ozempic) administered once weekly as an injection Semaglutide (Rybelsus) taken orally once daily (for type 2 diabetes only, not licensed for weight management) For weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities, two medications hold specific licences: Liraglutide 3.0 mg (Saxenda) once-daily subcutaneous injection Semaglutide 2.4 mg (Wegovy) once-weekly subcutaneous injection Access to these medications through the NHS is governed by NICE guidance
Key effects of GLP-1 injections include: Enhanced insulin secretion
L-citrulline only (2g/day of L-citrulline-malate)
GSH depletion does not induce mitochondrial superoxide or alter mitochondrial mass in RPE cells It has been suggested that mitochondria are predominant source of ROS upon H 2 O 2 -induced oxidative stress 7
This dual peptide blend pairs BPC-157 and TB-500 in a single lyophilised vial with 5mg of each, supplied as a high purity, COA verified powder for laboratory research
